JPWO2020073088A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020073088A5 JPWO2020073088A5 JP2021520168A JP2021520168A JPWO2020073088A5 JP WO2020073088 A5 JPWO2020073088 A5 JP WO2020073088A5 JP 2021520168 A JP2021520168 A JP 2021520168A JP 2021520168 A JP2021520168 A JP 2021520168A JP WO2020073088 A5 JPWO2020073088 A5 JP WO2020073088A5
- Authority
- JP
- Japan
- Prior art keywords
- lactobacillus
- disease
- inflammation
- gastrointestinal
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000186660 Lactobacillus Species 0.000 claims description 40
- 229940039696 Lactobacillus Drugs 0.000 claims description 20
- 206010061218 Inflammation Diseases 0.000 claims description 19
- 230000004054 inflammatory process Effects 0.000 claims description 19
- 241000186610 Lactobacillus sp. Species 0.000 claims description 17
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 15
- 210000001035 Gastrointestinal Tract Anatomy 0.000 claims description 14
- 241000577554 Lactobacillus zeae Species 0.000 claims description 14
- 210000003491 Skin Anatomy 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 14
- 210000001635 Urinary Tract Anatomy 0.000 claims description 13
- 239000012228 culture supernatant Substances 0.000 claims description 13
- 210000001503 Joints Anatomy 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 241000191682 Lactobacillus rapi Species 0.000 claims description 11
- 241000790171 Lactobacillus diolivorans Species 0.000 claims description 10
- 210000000282 Nails Anatomy 0.000 claims description 10
- 239000002609 media Substances 0.000 claims description 10
- 206010003816 Autoimmune disease Diseases 0.000 claims description 9
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims description 9
- 230000002496 gastric Effects 0.000 claims description 9
- 200000000018 inflammatory disease Diseases 0.000 claims description 9
- 206010060945 Bacterial infection Diseases 0.000 claims description 8
- 244000052616 bacterial pathogens Species 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 201000004624 dermatitis Diseases 0.000 claims description 6
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 206010028694 Nail disease Diseases 0.000 claims description 5
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 5
- 201000006704 ulcerative colitis Diseases 0.000 claims description 5
- 208000004998 Abdominal Pain Diseases 0.000 claims description 4
- 206010012735 Diarrhoea Diseases 0.000 claims description 4
- 208000008665 Gastrointestinal Disease Diseases 0.000 claims description 4
- 206010064147 Gastrointestinal inflammation Diseases 0.000 claims description 4
- 201000008286 diarrhea Diseases 0.000 claims description 4
- 201000002146 gastrointestinal system disease Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 206010000496 Acne Diseases 0.000 claims description 3
- 206010003246 Arthritis Diseases 0.000 claims description 3
- 206010009887 Colitis Diseases 0.000 claims description 3
- 208000005679 Eczema Diseases 0.000 claims description 3
- 210000000981 Epithelium Anatomy 0.000 claims description 3
- 206010021198 Ichthyosis Diseases 0.000 claims description 3
- 206010021197 Ichthyosis Diseases 0.000 claims description 3
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims description 3
- 206010037596 Pyelonephritis Diseases 0.000 claims description 3
- 241001303601 Rosacea Species 0.000 claims description 3
- 208000006641 Skin Disease Diseases 0.000 claims description 3
- 206010040872 Skin infection Diseases 0.000 claims description 3
- 206010040882 Skin lesion Diseases 0.000 claims description 3
- 208000002474 Tinea Diseases 0.000 claims description 3
- 241000893966 Trichophyton verrucosum Species 0.000 claims description 3
- 208000000143 Urethritis Diseases 0.000 claims description 3
- 206010046577 Urinary tract infection Diseases 0.000 claims description 3
- 201000005661 acute cystitis Diseases 0.000 claims description 3
- 201000003146 cystitis Diseases 0.000 claims description 3
- 231100000406 dermatitis Toxicity 0.000 claims description 3
- 231100001003 eczema Toxicity 0.000 claims description 3
- 239000001963 growth media Substances 0.000 claims description 3
- 201000004681 psoriasis Diseases 0.000 claims description 3
- 201000004700 rosacea Diseases 0.000 claims description 3
- 231100000444 skin lesion Toxicity 0.000 claims description 3
- 206010000060 Abdominal distension Diseases 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 206010011401 Crohn's disease Diseases 0.000 claims description 2
- 208000002925 Dental Caries Diseases 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 206010016952 Food poisoning Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 208000005577 Gastroenteritis Diseases 0.000 claims description 2
- 208000007565 Gingivitis Diseases 0.000 claims description 2
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 claims description 2
- 208000009883 Joint Disease Diseases 0.000 claims description 2
- 210000003750 Lower Gastrointestinal Tract Anatomy 0.000 claims description 2
- 208000007117 Oral Ulcer Diseases 0.000 claims description 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 2
- 230000001464 adherent Effects 0.000 claims description 2
- 230000001684 chronic Effects 0.000 claims description 2
- 210000002919 epithelial cells Anatomy 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 230000001717 pathogenic Effects 0.000 claims description 2
- 244000052769 pathogens Species 0.000 claims description 2
- 201000008838 periodontal disease Diseases 0.000 claims description 2
- 201000007100 pharyngitis Diseases 0.000 claims description 2
- 230000001737 promoting Effects 0.000 claims description 2
- 230000036269 ulceration Effects 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 3
- 206010056396 Asymptomatic bacteriuria Diseases 0.000 claims 2
- 206010018836 Haematochezia Diseases 0.000 claims 1
- 206010021425 Immune system disease Diseases 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 230000002522 swelling Effects 0.000 claims 1
- 230000002485 urinary Effects 0.000 claims 1
- 244000005700 microbiome Species 0.000 description 2
- 208000002399 Aphthous Stomatitis Diseases 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000003608 Feces Anatomy 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- 208000006551 Parasitic Disease Diseases 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 201000004538 bacteriuria Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
Description
ラクトバチルス・ディオリヴォランスＳＶＴ－０３は、受入番号ＬＭＧ Ｐ－３１２８７の下で、２０１９年２月２７日におけるベルギーの微生物の協調コレクション（ＢＣＣＭ）（Ｂｅｌｇｉａｎ Ｃｏｏｒｄｉｎａｔｅｄ Ｃｏｌｌｅｃｔｉｏｎｓ ｏｆ Ｍｉｃｒｏｏｒｇａｎｉｓｍｓ （ＢＣＣＭ）Ｆｅｄｅｒａｌ Ｐｕｂｌｉｃ Ｐｌａｎｎｉｎｇ Ｓｅｒｖｉｃｅ Ｓｃｉｅｎｃｅ Ｐｏｌｉｃｙ，８，ｒｕｅ ｄｅ ｌａ Ｓｃｉｅｎｃｅ Ｂ－１０００，Ｂｒｕｓｓｅｌｓ，Ｂｅｌｇｉｕｍ）と共にブダペスト条約に従って寄託される。
＜１＞ 対象における、炎症、炎症性疾患若しくは自己免疫疾患又はそれらに関連する１又は複数の症状を治療又は予防する方法であって、ラクトバチルス・ブチネリ、ラクトバチルス・ゼアエ、ラクトバチルス・ラピ、ラクトバチルス・パラカゼイ、ラクトバチルス・パラファラギニス及びラクトバチルス・ディオリヴォランスから選択されるラクトバチルス種、並びに／又は、前記ラクトバチルス種が培養された培養培地に由来する培養上清若しくは無細胞濾液を前記対象に投与することを含む、方法。
＜２＞ 前記炎症が、消化管、尿路、皮膚、爪又は関節の炎症である、＜１＞に記載の方法。
＜３＞ 前記炎症が、食中毒、下痢、胃潰瘍、口腔潰瘍、齲蝕又は歯周疾患に関連する、＜１＞又は＜２＞に記載の方法。
＜４＞ 前記１又は複数の炎症に関連する症状が、下痢、便の硬さの不足、糞便中の血液の存在、腹部疝痛、腹部膨満、腹部疼痛、消化管上皮内層の潰瘍、及び／又は歯肉の腫脹である、＜１＞から＜３＞のいずれか１つに記載の方法。
＜５＞ 前記炎症、炎症性疾患又は自己免疫疾患が、細菌感染、真菌感染、ウイルス感染若しくは寄生虫感染によって引き起こされるか、誘導されるか、又は、関連する、＜１＞から＜４＞のいずれか１つに記載の方法。
＜６＞ 前記炎症性疾患又は自己免疫疾患が、消化管、尿路、皮膚、爪又は関節の炎症性疾患又は自己免疫疾患である、＜１＞又は＜２＞に記載の方法。
＜７＞ 対象における、消化管、尿路、皮膚、爪又は関節の疾患を治療又は予防する方法であって、ラクトバチルス・ブチネリ、ラクトバチルス・ゼアエ、ラクトバチルス・ラピ、ラクトバチルス・パラカゼイ、ラクトバチルス・パラファラギニス及びラクトバチルス・ディオリヴォランスから選択されるラクトバチルス種、並びに／又は、前記ラクトバチルス種が培養された培地からに由来する培養上清若しくは無細胞濾液を前記対象に投与することを含み、前記疾患が、消化管、尿路、皮膚、爪若しくは関節の炎症に関連し、且つ／又は、前記疾患が、消化管、尿路、皮膚、前若しくは関節の感染によって引き起こされるか、若しくは前記感染に関連する、方法。
＜８＞ 前記消化管炎症又は消化管の疾患が、胃炎、胃腸炎若しくは炎症性腸疾患であるか、関連する、＜１＞から＜７＞のいずれか１つに記載の方法。
＜９＞ 前記疾患が過敏性腸症候群である、＜８＞に記載の方法。
＜１０＞ 前記炎症性腸疾患が大腸炎である、＜９＞に記載の方法。
＜１１＞ 前記大腸炎が潰瘍性大腸炎又はクローン病である、＜１０＞に記載の方法。
＜１２＞ 前記潰瘍性大腸炎が慢性潰瘍性大腸炎である、＜１１＞に記載の方法。
＜１３＞ 前記対象に、Ｌ．パラカゼイ、Ｌ．ブチネリ及びＬ．ゼアエの組み合わせ、又はＬ．ディオリヴォランス、Ｌ．パラファラギニス及びＬ．ブチネリの組み合わせが投与される、＜８＞から＜１２＞のいずれか１つに記載の方法。
＜１４＞ 前記消化管炎症又は消化管の疾患が、歯肉炎若しくは咽頭炎であるか、関連する、請求
項１＞から＜７＞のいずれか１つに記載の方法。
＜１５＞ 前記尿路の疾患が、膀胱炎、尿道炎、腎盂腎炎、無症状性細菌尿若しくはカテーテル関連尿路感染であるか、又は関連する、＜１＞に記載の方法。
＜１６＞ 前記皮膚又は爪の疾患が、乾癬、皮膚炎、湿疹、酒さ、座瘡、魚鱗癬、白癬であるか、関連し、又は炎症、斑、皮膚病変及び／若しくは感染を特徴とするか、関連する他の皮膚疾患若しくは爪疾患であるか、関連する＜１＞に記載の方法。
＜１７＞ 前記関節の疾患が関節炎であるか、又は関連する、＜１＞に記載の方法。
＜１８＞ 前記関節炎が関節リウマチ又は骨関節炎である、＜１７＞に記載の方法。
＜１９＞ 消化管、尿路、皮膚、爪又は関節の細菌感染を治療又は予防する方法であって、ラクトバチルス・ブチネリ、ラクトバチルス・ゼアエ、ラクトバチルス・ラピ、ラクトバチルス・パラカゼイ、ラクトバチルス・パラファラギニス及びラクトバチルス・ディオリヴォランスから選択されるラクトバチルス種、並びに／又は、前記ラクトバチルス種が培養された培地に由来する培養上清若しくは無細胞濾液を対象に投与することを含む、方法。
＜２０＞ 前記細菌感染が、炎症、炎症性疾患若しくは自己免疫疾患を生じさせるか、誘導するか又はそれ以外の形でこれらに関連する、＜１９＞に記載の方法。
＜２１＞ 前記細菌感染が、感染を生じさせる細菌の消化管上皮への付着及び／又は侵入に関連する、＜１９＞又は＜２０＞に記載の方法。
＜２２＞ 前記細菌感染が、消化管の炎症、若しくは消化管の炎症性疾患若しくは自己免疫疾患を生じさせるか、誘導するか又はそれ以外の形でこれらに関連する、＜１９＞から＜２１＞のいずれか１つに記載の方法。
＜２３＞ 対象において消化管粘膜への細菌性病原体の付着を阻害又は予防するための方法であって、ラクトバチルス・ブチネリ、ラクトバチルス・ゼアエ、ラクトバチルス・ラピ、ラクトバチルス・パラカゼイ、ラクトバチルス・パラファラギニス及びラクトバチルス・ディオリヴォランスから選択されるラクトバチルス種、並びに／又は、前記ラクトバチルス種が培養された培地に由来する培養上清若しくは無細胞濾液を前記対象に投与することを含む、方法。
＜２４＞ 対象において細菌性病原体が消化管上皮細胞に侵入することを阻害又は予防するための方法であって、ラクトバチルス・ブチネリ、ラクトバチルス・ゼアエ、ラクトバチルス・ラピ、ラクトバチルス・パラカゼイ、ラクトバチルス・パラファラギニス及びラクトバチルス・ディオリヴォランスから選択されるラクトバチルス種、並びに／又は、前記ラクトバチルス種が培養された培地に由来する培養上清若しくは無細胞濾液を前記対象に投与することを含む、方法。
＜２５＞ 前記細菌性病原体が、下部消化管にコロニーを作る病原体である、＜２３＞又は＜２４＞に記載の方法。
＜２６＞ 前記細菌性病原体が付着性侵入性大腸菌（ＡＩＥＣ）である、＜２５＞に記載の方法。
＜２７＞ 対象において創傷治癒を促進するための方法であって、ラクトバチルス・ブチネリ、ラ
クトバチルス・ゼアエ、ラクトバチルス・ラピ、ラクトバチルス・パラカゼイ、ラクトバチルス・パラファラギニス及びラクトバチルス・ディオリヴォランスから選択されるラクトバチルス種、並びに／又は、前記ラクトバチルス種が培養された培地に由来する培養上清若しくは無細胞濾液を前記対象に投与することを含む、方法。
＜２８＞ 前記ラクトバチルス種の内の２つ、３つ、４つ、５つ若しくは６つ全ての組み合わせ、又は前記ラクトバチルス種の内の２つ、３つ、４つ、５つ若しくは６つ全てが培養された培地に由来する培養上清若しくは無細胞濾液の投与を含む、＜１＞から＜２７＞のいずれか１つに記載の方法。
＜２９＞ 前記ラクトバチルス種、１又は複数の培養上清又は１又は複数の無細胞濾液が、医薬的に許容され得る組成物、食品又は飲料の形態で投与される、＜１＞から＜２８＞のいずれか１つに記載の方法。
＜３０＞ １又は複数のさらなる微生物又は他の治療剤の投与をさらに含む、＜１＞から＜２９＞のいずれか１つに記載の方法。
Lactobacillus diolivorans SVT-03 was submitted to the Belgian Coordinated Collections of Microorganisms (BCCM) Federal Public Planning on February 27, 2019 under accession number LMG P-31287. Service Science Policy, 8, rue de la Science B-1000, Brussels, Belgium) under the Budapest Treaty.
<1> A method of treating or preventing inflammation, inflammatory disease or autoimmune disease or one or more symptoms associated therewith in a subject, comprising Lactobacillus butinelli, Lactobacillus zeae, Lactobacillus rapi, a Lactobacillus species selected from Lactobacillus paracasei, Lactobacillus parafaraginis and Lactobacillus diolivorans, and/or a culture supernatant or cell-free filtrate derived from a culture medium in which said Lactobacillus species were cultured A method comprising administering to said subject.
<2> The method according to <1>, wherein the inflammation is inflammation of the digestive tract, urinary tract, skin, nails, or joints.
<3> The method according to <1> or <2>, wherein the inflammation is associated with food poisoning, diarrhea, gastric ulcer, oral ulcer, dental caries, or periodontal disease.
<4> The one or more inflammation-related symptoms include diarrhea, lack of stool consistency, presence of blood in feces, abdominal colic, abdominal distension, abdominal pain, ulceration of the lining of the gastrointestinal epithelium, and/or The method according to any one of <1> to <3>, which is gingival swelling.
<5><1> to <4>, wherein the inflammation, inflammatory disease, or autoimmune disease is caused, induced, or associated with bacterial infection, fungal infection, viral infection, or parasitic infection; A method according to any one of the preceding claims.
<6> The method according to <1> or <2>, wherein the inflammatory disease or autoimmune disease is an inflammatory disease or autoimmune disease of the gastrointestinal tract, urinary tract, skin, nails or joints.
<7> A method for treating or preventing diseases of the gastrointestinal tract, urinary tract, skin, nails or joints in a subject, comprising Lactobacillus butinelli, Lactobacillus zeae, Lactobacillus rapi, Lactobacillus paracasei, Lacto administering to said subject a Lactobacillus sp. selected from Bacillus parafaraginis and Lactobacillus diolivorans, and/or a culture supernatant or cell-free filtrate derived from a medium in which said Lactobacillus sp. wherein said disease is associated with inflammation of the gastrointestinal tract, urinary tract, skin, nails or joints and/or said disease is caused by infection of the gastrointestinal tract, urinary tract, skin, anterior or joints; or related to said infection.
<8> The method of any one of <1> to <7>, wherein the gastrointestinal inflammation or disease is or is associated with gastritis, gastroenteritis or inflammatory bowel disease.
<9> The method according to <8>, wherein the disease is irritable bowel syndrome.
<10> The method according to <9>, wherein the inflammatory bowel disease is colitis.
<11> The method according to <10>, wherein the colitis is ulcerative colitis or Crohn's disease.
<12> The method according to <11>, wherein the ulcerative colitis is chronic ulcerative colitis.
<13> The above-mentioned subject may contain L. Paracasei, L. Butinelli and L. A combination of L. zeae or L. zeae; Diolivolance, L. Parafaraginis and L. The method of any one of <8> to <12>, wherein a combination of Butinelli is administered.
<14> Claim that the gastrointestinal inflammation or gastrointestinal disease is or is related to gingivitis or pharyngitis
The method according to any one of items 1> to <7>.
<15> The method of <1>, wherein the disease of the urinary tract is or is associated with cystitis, urethritis, pyelonephritis, subclinical bacteriuria, or catheter-associated urinary tract infection.
<16> said skin or nail disease is or is associated with psoriasis, dermatitis, eczema, rosacea, acne, ichthyosis, ringworm, or is characterized by inflammation, plaque, skin lesions and/or infection or another related skin disease or nail disease, or the related method according to <1>.
<17> The method of <1>, wherein the joint disease is or is associated with arthritis.
<18> The method according to <17>, wherein the arthritis is rheumatoid arthritis or osteoarthritis.
<19> A method for treating or preventing bacterial infection of the gastrointestinal tract, urinary tract, skin, nails or joints, comprising: Lactobacillus butinelli, Lactobacillus zeae, Lactobacillus rapi, Lactobacillus paracasei, Lactobacillus paracasei A method comprising administering to a subject a Lactobacillus sp. selected from Parafaraginis and Lactobacillus diolivorans, and/or a culture supernatant or cell-free filtrate derived from a medium in which said Lactobacillus sp. .
<20> The method of <19>, wherein the bacterial infection causes, induces, or is otherwise associated with inflammation, an inflammatory disease, or an autoimmune disease.
<21> The method of <19> or <20>, wherein the bacterial infection is associated with adherence to and/or invasion of the gastrointestinal epithelium of infection-causing bacteria.
<22> said bacterial infection causes, induces, or is otherwise associated with inflammation of the gastrointestinal tract, or an inflammatory or autoimmune disease of the gastrointestinal tract, <19> to <21> A method according to any one of
<23> A method for inhibiting or preventing adhesion of bacterial pathogens to the gastrointestinal mucosa in a subject, comprising: Lactobacillus butinellii, Lactobacillus zeae, Lactobacillus rapi, Lactobacillus paracasei, Lactobacillus paracasei administering to said subject a Lactobacillus species selected from Parafaraginis and Lactobacillus diolivorans and/or a culture supernatant or cell-free filtrate derived from a medium in which said Lactobacillus species was cultured; Method.
<24> A method for inhibiting or preventing bacterial pathogens from invading gastrointestinal epithelial cells in a subject, comprising: Lactobacillus butinelli, Lactobacillus zeae, Lactobacillus rapi, Lactobacillus paracasei, Lacto administering to said subject a Lactobacillus sp. selected from Bacillus parafaraginis and Lactobacillus diolivorans and/or a culture supernatant or cell-free filtrate derived from a medium in which said Lactobacillus sp. including, method.
<25> The method of <23> or <24>, wherein the bacterial pathogen is a pathogen that colonizes the lower gastrointestinal tract.
<26> The method of <25>, wherein the bacterial pathogen is adherent invasive E. coli (AIEC).
<27> A method for promoting wound healing in a subject, comprising:
Lactobacillus species selected from Lactobacillus zeae, Lactobacillus rapi, Lactobacillus paracasei, Lactobacillus parafaraginis and Lactobacillus diolivorans and/or derived from the medium in which said Lactobacillus species were cultivated A method comprising administering a culture supernatant or cell-free filtrate to said subject.
<28> A combination of 2, 3, 4, 5 or all 6 of said Lactobacillus species, or 2, 3, 4, 5 or 6 of said Lactobacillus species The method of any one of <1> to <27>, comprising administering a culture supernatant or cell-free filtrate that is wholly derived from the culture medium.
<29><1> to <28, wherein the Lactobacillus sp., one or more culture supernatants or one or more cell-free filtrates are administered in the form of a pharmaceutically acceptable composition, food or beverage; The method according to any one of .
<30> The method of any one of <1> to <29>, further comprising administration of one or more additional microorganisms or other therapeutic agents.
Claims (16)
乾癬、皮膚炎、湿疹、酒さ、座瘡、魚鱗癬、白癬、又は炎症、斑、皮膚病変及び／若しくは感染を特徴とする若しくは炎症、斑、皮膚病変及び／若しくは感染に関連する他の皮膚疾患若しくは爪疾患であるか、
乾癬、皮膚炎、湿疹、酒さ、座瘡、魚鱗癬、白癬、又は炎症、斑、皮膚病変及び／若しくは感染を特徴とする若しくは炎症、斑、皮膚病変及び／若しくは感染に関連する他の皮膚疾患若しくは爪疾患に関連する、請求項１に記載のラクトバチルス種。 said skin or nail disease,
Psoriasis, dermatitis, eczema, rosacea, acne, ichthyosis, ringworm , or other skin characterized by or associated with inflammation, plaques, skin lesions and/or infections disease or nail disease,
Psoriasis, dermatitis, eczema, rosacea, acne, ichthyosis, ringworm, or other skin characterized by or associated with inflammation, plaques, skin lesions and/or infections 2. A Lactobacillus sp . according to claim 1, associated with a disease or nail disease .
said use is a combination of all 2, 3, 4, 5 or 6 of said Lactobacillus species, or 2, 3, 4, 5 or 6 of said Lactobacillus species 16. A Lactobacillus sp . according to any one of claims 1 to 15 , comprising administering to the subject a culture supernatant or cell-free filtrate wholly derived from the medium in which it was cultured.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018903823A AU2018903823A0 (en) | 2018-10-10 | Compositions and methods of treatment of conditions of the gastrointestinal tract | |
| AU2018903823 | 2018-10-10 | ||
| AU2018903822A AU2018903822A0 (en) | 2018-10-10 | Compositions and methods of treatment of inflammatory conditions and infections | |
| AU2018903822 | 2018-10-10 | ||
| AU2019901176A AU2019901176A0 (en) | 2019-04-05 | Compositions and methods of treatment of inflammatory conditions and associated infections | |
| AU2019901176 | 2019-04-05 | ||
| AU2019901175 | 2019-04-05 | ||
| AU2019901175A AU2019901175A0 (en) | 2019-04-05 | Compositions and methods of treatment of conditions of the gastrointestinal tract | |
| PCT/AU2019/051092 WO2020073088A1 (en) | 2018-10-10 | 2019-10-10 | Methods of treatment of inflammatory conditions and associated infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022504792A JP2022504792A (en) | 2022-01-13 |
| JPWO2020073088A5 true JPWO2020073088A5 (en) | 2022-10-19 |
Family
ID=70163621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021520168A Pending JP2022504792A (en) | 2018-10-10 | 2019-10-10 | How to treat inflammatory diseases and related infections |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210338749A1 (en) |
| EP (1) | EP3863656A4 (en) |
| JP (1) | JP2022504792A (en) |
| CN (1) | CN114206362A (en) |
| AU (1) | AU2019356524A1 (en) |
| CA (1) | CA3124725A1 (en) |
| SG (1) | SG11202103567RA (en) |
| WO (1) | WO2020073088A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4255456A1 (en) * | 2020-12-01 | 2023-10-11 | Servatus Ltd | Methods for improving sleep quality |
| WO2022120421A1 (en) * | 2020-12-09 | 2022-06-16 | Servatus Ltd | Combination therapy for inflammatory disorders of the joints |
| EP4387640A1 (en) * | 2021-08-19 | 2024-06-26 | Société des Produits Nestlé S.A. | Postbiotic |
| EP4387639A1 (en) * | 2021-08-19 | 2024-06-26 | Société des Produits Nestlé S.A. | Postbiotic |
| US20230141346A1 (en) * | 2021-11-05 | 2023-05-11 | Trillium Medical Products, LLC | Infused undergarment |
| WO2023097375A1 (en) * | 2021-12-02 | 2023-06-08 | Servatus Ltd | Methods for the treatment of constipation |
| CN115725469B (en) * | 2022-11-28 | 2024-05-14 | 广西大学 | Lactobacillus paracasei and application thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1306716B1 (en) * | 1999-06-21 | 2001-10-02 | Mendes S U R L | ASSOCIATION OF LACTIC BACTERIA AND ITS USE FOR THE PREVENTION AND / OR THERAPEUTIC TREATMENT OF INFECTIONS AND INFLAMMATORY STATES. |
| US20040208863A1 (en) * | 2003-01-30 | 2004-10-21 | James Versalovic | Anti-inflammatory activity from lactic acid bacteria |
| ITMI20032391A1 (en) * | 2003-12-05 | 2005-06-06 | Consiglio Nazionale Ricerche | MENSA OLIVES CONTAINING PROBIOTIC MICRO-ORGANISMS. |
| WO2009005379A1 (en) * | 2007-07-03 | 2009-01-08 | Danuta Kruszewska | New medical applications of alpha-ketoglutarate |
| JP4876262B2 (en) * | 2008-10-24 | 2012-02-15 | 防衛省技術研究本部長 | Novel plant lactic acid strain having anti-inflammatory effect, preventive and therapeutic agent, inhibitor and additive for inflammatory bowel disease or chronic diarrhea using the strain |
| US9138441B2 (en) * | 2009-12-31 | 2015-09-22 | Ira Milton Trachtman | Compositions and method for treatment and prophylaxis of inflammatory bowel disease |
| US9492487B2 (en) * | 2010-02-01 | 2016-11-15 | Matthew Ryan Garner | Microbial product containing multiple microorganisms |
| KR101918792B1 (en) * | 2011-05-16 | 2018-11-14 | 오르가노발란스 메디컬 아게 | Novel lactic acid bacteria and compositions containing them against bacterial colds |
| BR112015026773A2 (en) * | 2013-04-23 | 2017-07-25 | Terragen Holdings Ltd | bacterial strains that have antimicrobial activity and biological control compositions comprising the same |
| ITMI20130793A1 (en) * | 2013-05-14 | 2014-11-15 | Probiotical Spa | COMPOSITION INCLUDING LACTIC BACTERIA FOR USE IN THE PREVENTIVE AND / OR CURATIVE TREATMENT OF THE RECURRENT CYCLES. |
| KR20150023132A (en) * | 2013-08-23 | 2015-03-05 | (주) 아이투비 | Composit for improving atopic dermatitis |
| CN104000184A (en) * | 2013-12-09 | 2014-08-27 | 胡安然 | Food for alleviating atrophic gastritis |
| WO2016179639A1 (en) * | 2015-05-13 | 2016-11-17 | Markson Ro | Probiotic compositions and uses thereof |
| CN106860441B (en) * | 2017-02-10 | 2019-12-31 | 中国医学科学院医药生物技术研究所 | Application of 4-oxo-2-butenamide derivative in preparation of bacteriostatic agent |
| KR101917497B1 (en) * | 2017-02-18 | 2018-11-09 | 박병희 | Novel Lactobacillus buchneri and Use thereof |
| TWI607758B (en) * | 2017-03-07 | 2017-12-11 | 景岳生物科技股份有限公司 | Lactobacillus paracasei strain gmnl-653 and composition having the same for improving psoriasis symptoms |
| AU2018251616A1 (en) * | 2017-04-11 | 2019-10-17 | Servatus Ltd | Methods for the treatment of inflammation and inflammatory conditions |
| WO2019178309A1 (en) * | 2018-03-14 | 2019-09-19 | Sustainable Community Development, Llc | Probiotic composition and feed additive |
-
2019
- 2019-10-10 US US17/284,207 patent/US20210338749A1/en active Pending
- 2019-10-10 CA CA3124725A patent/CA3124725A1/en active Pending
- 2019-10-10 AU AU2019356524A patent/AU2019356524A1/en active Pending
- 2019-10-10 CN CN201980082026.6A patent/CN114206362A/en active Pending
- 2019-10-10 EP EP19870476.9A patent/EP3863656A4/en active Pending
- 2019-10-10 WO PCT/AU2019/051092 patent/WO2020073088A1/en unknown
- 2019-10-10 JP JP2021520168A patent/JP2022504792A/en active Pending
- 2019-10-10 SG SG11202103567RA patent/SG11202103567RA/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112534043B (en) | Lactobacillus paracasei strain and application thereof | |
| JP3944076B2 (en) | Probiotic products containing lactic acid bacteria | |
| JP3993168B2 (en) | Compositions comprising Lactobacillus pentosus strains and their use | |
| Meurman et al. | Recovery of Lactobacillus strain GG (ATCC 53103) from saliva of healthy volunteers after consumption of yoghurt prepared with the bacterium | |
| ES2269480T3 (en) | USE OF A LACTOBACILLUS strain that REDUCES THE RISK FACTORS ASSOCIATED WITH THE METABOLIC SYNDROME. | |
| US20020022019A1 (en) | Method of reducing ecologically adverse changes of the gastro intestinal microbial flora in patients under treatment with medicaments | |
| US20030180260A1 (en) | Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor | |
| JP2012512171A (en) | Compositions and methods for improved oral health | |
| EP1162987B1 (en) | Pharmaceutical composition for medical and veterinary use for regenerating intestinal flora in diarrhoea or dyspeptic syndrome | |
| US20160279180A1 (en) | Probiotic Strain of Lactobacillus Reuteri Exhibiting Anti-Helicobacter Activity, a Probiotic or Biotherapeutic Product Comprising Said Strain, and the Use Thereof | |
| JP2022504792A (en) | How to treat inflammatory diseases and related infections | |
| US20180353555A1 (en) | Compositions and methods for reducing flatulence | |
| WO2020098988A1 (en) | Strains, composition and method of use | |
| Vince | Metabolism of ammonia, urea, and amino acids, and their significance in liver disease | |
| JPWO2020073088A5 (en) | ||
| US11344587B2 (en) | Method of improving urogenital health using probiotic bacteria | |
| CN113633666A (en) | Probiotic micro-ecological preparation for treating oral halitosis and inflammation and preparation method and application thereof | |
| Shukla et al. | Probiotic characterization of lactobacilli and yeast strains isolated from whey beverage and therapeutic potential of Lactobacillus yoghurt in murine giardiasis | |
| JP2003527432A (en) | Use of lactic acid bacteria for the treatment of peritonitis | |
| JP2015180689A (en) | Agents and treatment for snoring and respiratory effort related arousals during sleep | |
| Thompson | Metabolism of neutral steroids | |
| Stjernquist-Desatnik | Persistence of Lactobacillus plantarum DSM 9843 on human tonsillar surface after oral administration in fermented oatmeal gruel: A pilot study | |
| Aji et al. | The Probiotic Role of Lactic Acid Bacteria (LAB) in Helicobacter Pylori Gastritis | |
| Petrushanko et al. | Therapeutic potential of lactobacilli-based drug in the treatment of generalized periodontitis | |
| Nikolov | Probiotics and mucosal immune response |